Research Groups

Navin Khanna

Recombinant Gene Products

Group Leader

Research Interests and Description

Navin Khanna

International Centre for Genetic Engineering and Biotechnology
Aruna Asaf Ali Marg
110 067 New Delhi, India

E-mail: navinicgeb.res.in
Office tel: +91-11-26742357/60, 26741358, 2741361
Office fax: +91-11-26742316

Education

University of Lucknow, Department of Biochemistry, Lucknow, India, MSc, 1977
All India Institute of Medical Sciences, Department of Biochemistry, New Delhi, India, PhD, 1983

Career History

Since 2015, Adjunct Professor, School of Medicine, Emory University, Atlanta GA, USA
Since 2012, Adjunct Professor and  Co-Director, Centre of Bio-design and Diagnostics, Translational Health Sciences and Technology (THSTI), NCR, Haryana, India
Since 1994, Group Leader, Recombinant Gene Products Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
1990-1994, Senior Research Scientist, ICGEB, New Delhi.
1989-1990, Research Assistant Professor, Department of Biochemistry and Molecular Biology, University of California, Irvine, USA.
1989-1987, Postgraduate Research Biologist, Centre for Molecular Genetics, University of California, San Diego, USA.
1987-1983, Alberta Heritage Foundation Fellow at Cell Regulation Group, University of Calgary, Alberta, Canada.

Teaching Activity

Tutoring in the ICGEB Ph.D. Programme.

Scientific Activity

Current research focuses on genetically engineered biomolecules of medical use. A primary contribution is in the development of novel recombinant designer proteins as inexpensive, highly sensitive and specific diagnostic intermediates for viral infections, like HCV, HIV and Dengue virus. Diagnostic kits based on these proteins have been commercialized. The rapid HCV and HIV tests developed, based on our designer proteins, have CE certifications and are being sold in several countries. The availability of these designer proteins and high affinity Hepatitis B virus monoclonal antibodies has reduced the production cost of these diagnostic kits for detection of HCV and HBV infections. In collaboration with Prof. Kim Pettersson at the University of Turku, Finland, these designer proteins are being explored for developing novel reporter assays using Terbium-labelled nanoparticles. A prototype dual assay for the simultaneous detection of HIV and HBV infections has been developed. Work is underway to build upon this to create a unique 3-in-1 assay for the simultaneous detection of HIV, HBV and HCV infections, for use in blood bank settings. Based on our “know-how”, a 3-in-1 dengue test (Dengue Day 1) has been developed by an Indian company for simultaneous point-of-care detection of Dengue NS1 Antigen & differential   detection of IgM & IgG antibodies in Human Serum/ Plasma. This kit has been launched in 2011 and has been a great success on the Indian market.

Earlier, we had developed a high copy Pichia pastoris clone for the laboratory scale production of HBsAg. This “know-how” has been successfully transferred to pharmaceutical companies in Iran and Egypt. Recently, in collaboration with Professor Ursula Rinas at Helmholtz Institute of Infection Research, we have designed a simple two-phase high-cell density fed batch procedure composed of a glycerol batch and a constant methanol fed-batch phase based on robust FID online analytics which is proposed to generate ~7 times more HBsAg than previously reported using Pichia-based expression systems. Using this robust feeding protocol, maximum concentrations of ~7 grams HBsAg per liter culture broth were obtained. The amount of soluble HBsAg, competent for assembly into characteristic virus-like particles (VLPs), an attribute critical to its immunogenicity and efficacy as a hepatitis B vaccine, reached 2.3 grams per liter of culture broth. These research findings have been extended to a tri-party collaboration with the Technology transfer group at ICGEB Trieste, and the German group, for the enhanced production of human insulin. Currently, our efforts have resulted in the secretion of 3 gram of insulin precursor from recombinant Pichia pastoris. These clones for the production of r-HBsAg and human-recombinant insulin have been transferred to a biotechnology company in China.

Other research interests include anti dengue and anti HCV compounds from natural sources and development of experimental Dengue tetravalent subunit vaccine in yeast.

Awards and honors include:
Fellow of Indian National Science Academy (2017)
Fellow of Indian Academy of Sciences (2016)
Fellow of National Academy of Sciences (2015)
Organization of Pharmaceutical Producers of India, Scientist Award (2015)
Om Prakash Bhasin Foundation Award in Biotechnology (2013)
Ranbaxy Research Award in Pharmaceutical Sciences, by Ranbaxy Science Foundation (2012)
Biotech Commercialization Award by Department of Biotechnology, Govt. of India (2011)
VASVIK Industrial Research Award in Biological Science and Technology (2007)

Selected Publications

Sharma, C., Sankhyan, A., Sharma, T., Khan, N., Chaudhuri, S., Kumar, N., Bhatnagar, S., Khanna, N., Tiwari, A. 2015. A repertoire of high-affinity monoclonal antibodies specific to S. typhi: as potential candidate for improved typhoid diagnostic Immunol Res 62, 325-340 doi: 10.1007/s12026-015-8663-z PubMed link

Talha, S.M., Juntunen, E., Salminen, T., Sangha, A., Vuorinen, T., Khanna, N., Pettersson, K. 2015.  All-in-one dry-reagent time-resolved immunofluorometric assay for the rapid detection of HIV-1 and -2 infections. J Virol Methods 226, 52-59 PubMed link

Beesetti, H., Khanna, N., Swaminathan, S. 2014. Drugs for dengue: a patent review Expert Opin Ther Pat 24, 1171-1184 PubMed link

Talha, S.M., Hytönen, J., Westhorpe, A., Kumar, S., Khanna, N., Pettersson, K. 2013. Europium nanoparticle based high performing immunoassay for the screening of treponemal antibodies. PLoS One 8 PubMed link

Khetarpal, N., Poddar, A., Nemani, S.K., Dhar, N., Patil, A., Negi, P., Perween, A., Viswanathan, R., Lünsdorf, H., Tyagi, P., Raut, R., Arora, U., Jain, S.K., Rinas, U., Swaminathan, S., Khanna, N. 2013. Dengue-specific subviral nanoparticles: design, creation and characterization. J Nanobiotechnology doi: 10.1186/1477-3155-11-15 PubMed link

Swaminathan, S., Khanna, N., Herring, B., Mahalingam, S. 2013. Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 13, 3, 191-192 PubMed link

Arora, U., Tyagi, P., Swaminathan, S., Khanna, N. 2013. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine 31, 6, 873-878 PubMed link

Swaminathan, S., Khanna, N. 2013. Experimental dengue vaccines. In: Molecular Vaccine-From Prophylaxis to Therapy (Editor: M. Giese), Springer-Verlag, Heidelberg

Patents

N. Khanna and V. Ramasamy. Vaccine. WO 2016/034974 A1.

P.K. Bhatnagar, C. K. Katiyar, N. Khanna, D. J. Upadhyay, S. Swaminathan, K. Srinivas, N. Sharma, A. Kanaujia, R. Sood, S. Singhal, G. Shukla, R. Duggar, P. K. Pareek, Y. Singh, S. Khan, and R. Raut. Use of Cissampelos pariera extracts for treating dengue. US 20160243182 A1

P.K. Bhatnagar, C. K. Katiyar, N. Khanna, D. J. Upadhyay, S. Swaminathan, K. Srinivas, N. Sharma, A. Kanaujia, R. Sood, S. Singhal, G. Shukla, R. Duggar, P. K. Pareek, Y. Singh, S. Khan, and R. Raut. Anti-dengue activity of Cissampelos pariera extracts. US 2012/0107424 A1

P.K. Bhatnagar, C. K. Katiyar, N. Khanna, D. J. Upadhyay, S. Swaminathan, K. Srinivas, N. Sharma, A. Kanaujia, R. Sood, S. Singhal, G. Shukla, R. Duggar, P. K. Pareek, Y. Singh, S. Khan, and R. Raut. Anti-dengue activity of Cissampelos pariera extracts. EP2389184

P.K. Bhatnagar, C. K. Katiyar, N. Khanna, D. J. Upadhyay, S. Swaminathan, K. Srinivas, N. Sharma, A. Kanaujia, R. Sood, S. Singhal, G. Shukla, R. Duggar, P. K. Pareek, Y. Singh, S. Khan, and R. Raut. Anti-dengue activity of Cissampelos pariera extracts. CN102361644 (A)

ICGEB New Delhi

ICGEB Campus
Aruna Asaf Ali Marg
110 067 New Delhi
INDIA
Tel: +91-11-26741358/1007
Fax: +91-11-26742316
icgebicgeb.res.in

tl_files/iTunes_Badge_Color_master_10251024.png

 

 

tl_files/FB.png tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png